Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Cholangiocarcinoma Non-resectable
- Interventions
- Procedure: DEB-TACE
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06192784
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Cholangiocarcinoma Non-resectable
- Interventions
- Procedure: HAIC
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06192797
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Three Dimensional Navigation IntraCardiac Guidance Kit for Atrial Septal Puncture
Not Applicable
Recruiting
- Conditions
- Atrial Fibrillation
- Interventions
- Device: Three-Dimensional Navigation Atrial Septal PunctureDevice: Conventional Atrial Septal Puncture
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT06188351
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: HAIC
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06187961
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Accuracy of Static Navigation Systems and Robotic System in Partially Edentulous in Posterior Area
Not Applicable
Not yet recruiting
- Conditions
- Dental Implant
- Interventions
- Procedure: robotic systemProcedure: Static navigation system
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06173921
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Phase 2
Recruiting
- Conditions
- Breast Cancer With Brain Metastases
- Interventions
- Drug: pyrotinib+capecitabine+bevacizumab
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06152822
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06149130
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT06121609
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 360
- Registration Number
- NCT06089369
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Phase 3
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT06089382
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
© Copyright 2025. All Rights Reserved by MedPath